Literature DB >> 12544723

Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients.

Gabriela F de Larrañaga1, Alejandro Petroni, Gabriel Deluchi, Beatriz S Alonso, Jorge A Benetucci.   

Abstract

The endothelium participates in haemostasis, inflammation, blood pressure regulation and other physiological systems. Consequently, endothelial dysfunction has been related to hypertension, thrombosis and atherosclerosis. Both von Willebrand factor (vWF) and tissue-type plasminogen activator (t-PA) are synthesized by the endothelium and their plasma levels increased during endothelium activation or injury. So far, they are well-known markers of endothelial cell function. Many circumstances activate or damage the endothelium, such as viruses, bacterium and inflammation. Circulating vWF and t-PA were studied in 92 unselected human immunodeficiency virus-1 (HIV-1)-infected patients [27 patients with and 65 patients without acquired immunodeficiency syndrome (AIDS)] and correlated with plasma levels of pro-inflammatory cytokines (tumour necrosis factor-alpha, interleukin-6), viral load, CD4 T-cell count and infectious status. HIV-1-infected patients had significantly higher plasma levels of vWF (152 versus 90%), tumour necrosis factor-alpha (31.3 versus 9.0 pg/ml) and interleukin-6 (3.5 versus 1.9 pg/ml) but not t-PA (5.9 versus 4.2 ng/ml) than the control group. These two endothelial markers correlated significantly with viral load and interleukin-6 levels in HIV-1-infected patients. The highest levels of vWF and t-PA were found in patients with AIDS. In conclusion, endothelial cell perturbation is present in HIV infection and may be a consequence of different mechanisms such as viral load, cytokines and advanced diseases. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544723     DOI: 10.1097/00001721-200301000-00004

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  21 in total

1.  Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia.

Authors:  Anne-Mette Lebech; Ulrik Sloth Kristoffersen; Niels Wiinberg; Kristian Kofoed; Ove Andersen; Birger Hesse; Claus Leth Petersen; Jan Gerstoft; Andreas Kjaer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

2.  Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Jessica L Montoya; Jennifer Iudicello; Hannah A Oppenheim; Pariya L Fazeli; Michael Potter; Qing Ma; Paul J Mills; Ronald J Ellis; Igor Grant; Scott L Letendre; David J Moore
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

Review 3.  Current update on HIV-associated vascular disease and endothelial dysfunction.

Authors:  Hong Mu; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

4.  Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.

Authors:  Fiona C Lampe; Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; Erik Stroes; David A Cooper; Jennifer Hoy; Nick I Paton; Nina Friis-Møller; Jacquie Neuhaus; Angelike P Liappis; Andrew N Phillips
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

5.  Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats.

Authors:  Wenwen Zheng; Wan Huang; Shue Liu; Roy C Levitt; Keith A Candiotti; David A Lubarsky; Shuanglin Hao
Journal:  Anesth Analg       Date:  2014-09       Impact factor: 5.108

6.  Monocyte CD49e and 110-120 kDa fibronectin fragments: HIV prognostic indicators independent of viral load and CD4 T-cell counts.

Authors:  Roger D Rossen; Jose A Rubio; Wendy J Porter; JoAnn Trial; Frank M Orson; Maria C Rodriguez-Barradas; Holly H Birdsall
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

7.  Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis.

Authors:  A A Higazi; M El-Haj; A Melhem; A Horani; O Pappo; C E Alvarez; N Muhanna; S L Friedman; R Safadi
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

8.  Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Maxwell Pistilli; Aidan Hancock; Griffin Reynolds; Cecile Gallo; Joe Ondercin; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

9.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.